BlackRock Institutional Trust’s PTC Therapeutics PTCT Stock Holding History

BlackRock Institutional Trust’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$10.7M	Buy	983,090 +83,844	+9%	+$880K	﹤0.01%	2358
2016 Q3	$12.6M	Buy	899,246 +86,489	+11%	+$703K	﹤0.01%	2196
2016 Q2	$5.71M	Buy	812,757 +1,985	+0.2%	+$14.6K	﹤0.01%	2613
2016 Q1	$5.22M	Buy	810,772 +3,459	+0.4%	+$60K	﹤0.01%	2639
2015 Q4	$26.2M	Buy	807,313 +16,416	+2%	+$483K	﹤0.01%	1676
2015 Q3	$21.1M	Buy	790,897 +155,612	+24%	+$6.66M	﹤0.01%	1804
2015 Q2	$30.6M	Buy	635,285 +58,447	+10%	+$3.41M	﹤0.01%	1619
2015 Q1	$35.1M	Buy	576,838 +167,131	+41%	+$10.2M	0.01%	1557
2014 Q4	$21.2M	Buy	409,707 +165,005	+67%	+$7.26M	﹤0.01%	1859
2014 Q3	$10.8M	Sell	244,702 -16,493	-6%	-$516K	﹤0.01%	2289
2014 Q2	$6.83M	Buy	261,195 +120,600	+86%	+$2.58M	﹤0.01%	2630
2014 Q1	$3.67M	Buy	140,595 +37,181	+36%	+$999K	﹤0.01%	2900
2013 Q4	$1.75M	Buy	103,414 +46,285	+81%	+$813K	﹤0.01%	3218
2013 Q3	$1.23M	Buy	+57,129	New	+$993K	﹤0.01%	3304

Other funds holding PTCT

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock Institutional Trust's PTCT Position: Q4 2016 in Review

BlackRock Institutional Trust increased its PTC Therapeutics (PTCT) stake by 9.3% in Q4 2016, buying an estimated $880K and bringing the position to 983,090 shares worth $10.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2358.

BlackRock Institutional Trust first reported a position in PTCT in Q3 2013 and has held it in 14 quarters since. The position peaked at $35.1M in Q1 2015. 123 funds tracked by Wall St. Rank hold PTCT as of Q4 2016.

BlackRock Institutional Trust held 983,090 shares of PTC Therapeutics worth $10.7M as of Q4 2016.
BlackRock Institutional Trust bought 83,844 PTC Therapeutics shares in Q4 2016, an estimated $880K.
PTC Therapeutics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2358 holding.
BlackRock Institutional Trust first reported a position in PTC Therapeutics in Q3 2013 and has held it in 14 quarters since.
BlackRock Institutional Trust's PTC Therapeutics position peaked at $35.1M in Q1 2015.
123 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.